Tradestie Institutional Equity Comparison Engine
EKSO vs CLSD โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
EKSO Overall Edge
EKSO Captures Institutional Edge (2โ0 Pillars ยท 7โ1 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Ekso Bionics Holdings, Inc. Common Stock (EKSO) driven by superior Growth & Margin, Momentum & Technical. Fundamentally, EKSO trades at N/M Forward P/E with -119.7% operating margin (-38.3% YoY revenue) versus CLSD at N/M Forward P/E and -3502.5% operating margin (-80.6% YoY). In options structure, EKSO sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against CLSD sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).
Valuation Winner
Tie
EKSO N/M vs CLSD N/M Fwd P/E
Growth & Margin Winner
EKSO
Op Margin -119.7% vs -3502.5% ยท YoY -38.3% vs -80.6%
Momentum & Technical Winner
EKSO
1Y +62.6% vs -97.5% ยท 52W Pos 87% vs 1%
Options & Structure Winner
Tie
UNCLASSIFIED (N/A IV) vs UNCLASSIFIED (N/A IV)
EKSO
NASDAQ
Ekso Bionics Holdings, Inc. Common Stock
General Industrial Machinery & Equipment, Nec
$11.80
+0.08% 1D
Market Cap
$42.0M
1M Return
+25.53%
1Y Return
+62.6%
Forward P/E
N/M
Unified AI Score
58.1 / 100
HOLD
Tech 60.0
Fund 54.0
Flow 50.0
Mom 50.0
CLSD
NASDAQ
Clearside Biomedical, Inc. Common Stock
Pharmaceutical Preparations
$0.41
-26.96% 1D
Market Cap
$2.9M
1M Return
-88.86%
1Y Return
-97.47%
Forward P/E
N/M
Unified AI Score
43.3 / 100
HOLD
Tech 40.0
Fund 43.0
Flow 50.0
Mom 40.0
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
EKSO +62.6%
CLSD -97.47%
Spread: +61.97 pp (EKSO Lead)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
EKSO TTM Op. Margin: -119.7%
CLSD TTM Op. Margin: -3502.5%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on EKSO vs CLSD. Trailing 12-month operating profitability (EKSO -119.7% vs CLSD -3502.5%) and valuation multiples (EKSO N/M vs CLSD N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | EKSO | CLSD | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $42.0M | $2.9M | Larger Scale | EKSO |
| Trailing P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Forward P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Revenue Growth (YoY) Growth | -38.3% | -80.6% | Higher Growth | EKSO |
| Operating Margin (TTM) Profitability | -119.7% | -3502.5% | Higher Margin | EKSO |
| Net Profit Margin Profitability | -91.4% | 0.0% | Higher Margin | CLSD |
| Return on Equity (ROE) Capital Efficiency | -107.6% | -1310.0% | Higher ROE | EKSO |
| 52-Week Range Position Momentum | 87% ($0โ$14) | 1% ($0โ$17) | Stronger Trend | EKSO |
| Beta / 30D Volatility Risk Regime | 2.16ฮฒ ยท 76% Vol | 2.24ฮฒ ยท 269% Vol | Lower Realized Risk | EKSO |
| Unified Institutional Score Composite Signal | 58.1 / 100 (HOLD) | 43.3 / 100 (HOLD) | Higher Composite | EKSO |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full EKSO vs CLSD Buy Guide
EKSO
UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
N/A
IV Regime
Unclassified
CLSD
UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
N/A
IV Regime
Unclassified
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither EKSO nor CLSD registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.